Video Experimental Relacionado

Updated: Sep 9, 2025

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Vinorelbina con o sin tiotepa para el cáncer de mama metastásico HER2- negativo: un análisis de la puntuación de

Aurelia Robert¹, Paul Gougis^1,2,3, Elise Dumas³

¹Department of Medical Oncology, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié-Salpêtrière Hospital, Paris, France.

Cancer medicine

|August 29, 2025

Resumen

La adición de tiotepa a la vinorelbina no mejoró la supervivencia global para el cáncer de mama metastásico (MBC). Sin embargo, la combinación mostró una mejoría en la supervivencia libre de progresión (SFP) en pacientes con metástasis cerebrales.

Área de la Ciencia:

En el campo de la oncología
Farmacología
Ensayos clínicos

Sus antecedentes:

La vinorelbina es un tratamiento estándar para el cáncer de mama metastásico (MBC).
Thiotepa es conocido por su capacidad para penetrar la barrera hematoencefálica, lo que sugiere una utilidad potencial en las metástasis del SNC.

Objetivo del estudio:

Comparar la eficacia y la seguridad de la vinorelbina con o sin tiotepa en pacientes con mBC HER2-negativos.
Evaluar el impacto de la adición de tiotepa en la supervivencia libre de progresión (SFP), la supervivencia global (SG) y el control de la enfermedad del sistema nervioso central (SNC).

Principales métodos:

Diseño del estudio retrospectivo.
Puntuación de propensión de la probabilidad inversa de ponderación del tratamiento (IPTW) utilizada para la comparabilidad del grupo.
Análisis de la SFP, del SOP, de la SFP del SNC y de los acontecimientos adversos.

Principales resultados:

No hay diferencias significativas en la mediana de la SFP u OS entre la vinorelbina- tiotepa y la vinorelbina en monoterapia.
La vinorelbina tiotepa demostró una SFP y SFP-SNC significativamente más largas en el subgrupo de metástasis del SNC.
Se observó una mayor incidencia de eventos adversos de grado ≥3 con el tratamiento combinado.

Conclusiones:

La combinación de vinorelbina y tiotepa no mejoró la SFP u OS en mBC HER2-negativos.
El tratamiento combinado puede ofrecer un beneficio en la supervivencia de los pacientes con metástasis en el SNC.
Se debe tener en cuenta el aumento de la toxicidad cuando se utiliza vinorelbina- tiotepa.

Palabras clave:

cáncer de mama puntuación de propensión Pruebas del mundo real Tiotepa y sus derivados Sin embargo, no se incluyen los siguientes:

Más Videos Relacionados

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Videos de Conceptos Relacionados

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...